### Guideline Page and Request

**KID-1 Internal request:**
Review the data for the inclusion of adjuvant sunitinib as a treatment option after primary treatment with nephrectomy.

### Panel Discussion/References

Based on the available data and the recent FDA approval, the panel consensus was to include adjuvant sunitinib as an option for patients with clear cell histology and high-risk (defined as tumor stage 3 or higher, regional lymph-node metastasis, or both). This was added with a category 2B designation.


### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>5</td>
<td>1</td>
<td>6</td>
</tr>
</tbody>
</table>